| Mrs Janell J Fenn, NP | |
|
600 Celebrate Life Pkwy, Newnan, GA 30265-8001 | |
| (770) 400-6000 | |
| Not Available |
| Full Name | Mrs Janell J Fenn |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 600 Celebrate Life Pkwy, Newnan, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245832971 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RX0202X | Internal Medicine - Medical Oncology | RN188392 (Georgia) | Secondary |
| 363L00000X | Nurse Practitioner | RN188392 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Preferred Healthcare Llc | 3678946571 | 2 |
News Archive
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has received commitments from institutional investors to purchase US$15 million of securities in a registered direct offering.
It could take a mere 30 seconds to spot signs of Alzheimer's disease in 40 year-olds in the near future say scientists who are developing a new diagnostic test. Usually Alzheimer's disease is detected much later in life after the symptoms begin to appear.
A study of real-world exposure to non-ionizing radiation from magnetic fields in pregnant women found a significantly higher rate of miscarriage, providing new evidence regarding their potential health risks.
Catalyst Pharmaceutical Partners, Inc. today announced positive results from a series of CPP-115 preclinical safety and efficacy evaluations. CPP-115 was found to have a significantly improved retinal safety profile compared to vigabatrin.
› Verified 7 days ago
| Entity Name | Ctca Physicians Group Of Georgia, Llc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447520333 PECOS PAC ID: 4880841212 Enrollment ID: O20120820001117 |
News Archive
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has received commitments from institutional investors to purchase US$15 million of securities in a registered direct offering.
It could take a mere 30 seconds to spot signs of Alzheimer's disease in 40 year-olds in the near future say scientists who are developing a new diagnostic test. Usually Alzheimer's disease is detected much later in life after the symptoms begin to appear.
A study of real-world exposure to non-ionizing radiation from magnetic fields in pregnant women found a significantly higher rate of miscarriage, providing new evidence regarding their potential health risks.
Catalyst Pharmaceutical Partners, Inc. today announced positive results from a series of CPP-115 preclinical safety and efficacy evaluations. CPP-115 was found to have a significantly improved retinal safety profile compared to vigabatrin.
› Verified 7 days ago
| Entity Name | Preferred Healthcare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639884117 PECOS PAC ID: 3678946571 Enrollment ID: O20230223001529 |
News Archive
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has received commitments from institutional investors to purchase US$15 million of securities in a registered direct offering.
It could take a mere 30 seconds to spot signs of Alzheimer's disease in 40 year-olds in the near future say scientists who are developing a new diagnostic test. Usually Alzheimer's disease is detected much later in life after the symptoms begin to appear.
A study of real-world exposure to non-ionizing radiation from magnetic fields in pregnant women found a significantly higher rate of miscarriage, providing new evidence regarding their potential health risks.
Catalyst Pharmaceutical Partners, Inc. today announced positive results from a series of CPP-115 preclinical safety and efficacy evaluations. CPP-115 was found to have a significantly improved retinal safety profile compared to vigabatrin.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Janell J Fenn, NP 600 Celebrate Life Pkwy, Newnan, GA 30265-8001 Ph: (770) 400-6000 | Mrs Janell J Fenn, NP 600 Celebrate Life Pkwy, Newnan, GA 30265-8001 Ph: (770) 400-6000 |
News Archive
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has received commitments from institutional investors to purchase US$15 million of securities in a registered direct offering.
It could take a mere 30 seconds to spot signs of Alzheimer's disease in 40 year-olds in the near future say scientists who are developing a new diagnostic test. Usually Alzheimer's disease is detected much later in life after the symptoms begin to appear.
A study of real-world exposure to non-ionizing radiation from magnetic fields in pregnant women found a significantly higher rate of miscarriage, providing new evidence regarding their potential health risks.
Catalyst Pharmaceutical Partners, Inc. today announced positive results from a series of CPP-115 preclinical safety and efficacy evaluations. CPP-115 was found to have a significantly improved retinal safety profile compared to vigabatrin.
› Verified 7 days ago